Creating a personalized model to test drug responses in pancreatic cancer
Official title: Personalized Organoid-Chip Model For Drug Testing in Pancreatic Cancer
Funded at University of Texas Hlth Sci Ctr Houston · NIH-11113431 · Data updated 2026-11-12
This study is working on a special tool that helps doctors understand how your unique pancreatic cancer tumor might respond to different treatments, so they can choose the best option just for you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $120,139 |
| NIH project number | 7R21CA277110-03 |
| Project ID | NIH-11113431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic cancer who are seeking personalized treatment options.
✕Less likely to help
Patients with cancers other than pancreatic cancer may not benefit from this specific research.
What this research studies
This research aims to develop a personalized platform that predicts how individual pancreatic cancer tumors respond to various treatments. By using 3D patient-derived organoids and advanced microfluidic technologies, the project will create a tumor-chip device that mimics the tumor microenvironment. This device will allow researchers to assess the effectiveness of both conventional and novel therapies on a patient's specific tumor, ultimately guiding personalized treatment decisions. The goal is to enhance the accuracy and reliability of treatment predictions for patients with pancreatic cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tailored treatment options for patients with pancreatic cancer.
How similar studies have gone: Other research has shown promise in using personalized models for drug testing in various cancers, indicating potential success for this approach.
Where this research is happening
-
University of Texas Hlth Sci Ctr Houston
Houston, United States Active
Researchers
- Principal investigator: Bishehsari, Faraz — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Bishehsari, Faraz
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.